About Stoic Bio

David Sheehan is the Founder, President, and CEO of Stoic Bio. He has led the development of novel capital equipment that radically changes the delivery of cell culture media, with a focus on sustainability. Prior to Stoic Bio, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO of Digirad, a cardiovascular imaging company that he took public in 2004, and in leadership positions at Baxter and Haemonetics. Dave also founded and is currently the CEO of Nucleus Biologics, (Stoic Bio's sister company), where he leads the development of innovative cell culture tools to simplify and accelerate the design, customization, and ordering of cell culture media products. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.

Will has over 30 years of experience in financial and business leadership roles across a diverse range of industries, including wireless technologies, internet of things devices, and cosmeceuticals. Will serves as CFO for both Stoic Bio and sister company Nucleus Biologics. Previously, Will was the Senior VP of Finance and Operations for SENTE, and before that, was the CFO of LocusTraxx, leading the company to a successful acquisition exit. Will also spent 12 years at Qualcomm in various leadership roles across multiple divisions including new business development, finance lead for the successful acquisition of a business from Alcatel, and leading international finance and business operations for Qualcomm’s Omnitracs division. Will has a BS degree in accounting from Purdue University and an MBA in Finance with honors from the University of North Texas.

Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry prior to joining Stoic Bio and its sister company, Nucleus Biologics, as Vice President of Marketing. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.

Sarah currently serves as Vice President at the Tavistock Group where she manages investments in the food, agriculture, health and technology sectors. She has experience in finance, operations, investments and marketing. Sarah also holds a Bachelor of Economics and a Bachelor of Commerce from the University of Queensland.

Dr. Alexandra Silverton is an assistant professor at University of Central Florida and a board-certified Internal Medicine physician. Dr. Silverton also serves as Medical Director for Tavistock Development Company in Lake Nona’s Health and Life Sciences cluster. Prior to joining Tavistock in 2019, Dr. Silverton worked as an assistant professor and an academic hospitalist at both Tulane University and Emory University. Dr. Silverton received her Bachelor of Science Degree in Biology from Duke University and her MD from Emory University School of Medicine. Dr. Silverton also holds a Master’s degree in Public Health from the Rollins School of Public Health at Emory University. Dr. Silverton completed her Internal Medicine residency at New York University (NYU).

Kieran was Chairman of the Board and Chief Executive Officer of CareFusion Corporation from 2011 until March 2015 when it was sold to Becton Dickinson. Previously, Kieran joined ResMed in 2003 as President and Chief Operating Officer of the Americas, was promoted to the role of President and Chief Operating Officer of ResMed Global in 2004, and Chief Executive Officer and Director in 2008. Kieran also served on the board of Volcano Corporation until 2015. Prior to 2002, Kieran held various marketing, sales, and financial positions within Nanogen, Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company. Kieran currently sits on the board of directors of Edwards Lifesciences and Arena Pharmaceuticals. Kieran has a bachelor’s degree from the Rutgers University College of Agricultural and Biological Sciences and an MBA from Harvard Business School.

Neil has more than 30 years of business experience with emphasis on operations, legal, tax, investments, and finance. Neil has worked with the biopharmaceutical industry since 2004. In addition, Neil has worked at various multinational companies, including Tavistock Group, Arthur Andersen, and Amoco Corporation. Neil received his Juris Doctor from the University of Pennsylvania Law School and his Bachelor of Science in Accountancy from the University of Illinois.

David Sheehan is the Founder, President, and CEO of Stoic Bio. He has led the development of novel capital equipment that radically changes the delivery of cell culture media, with a focus on sustainability. Prior to Stoic Bio, Dave was COO of Volcano Corporation, a publicly held life sciences company that was sold to Philips for $1.2 billion. Previous to Volcano, Dave was the CEO of Digirad, a cardiovascular imaging company that he took public in 2004, and in leadership positions at Baxter and Haemonetics. Dave also founded and is currently the CEO of Nucleus Biologics, (Stoic Bio's sister company), where he leads the development of innovative cell culture tools to simplify and accelerate the design, customization, and ordering of cell culture media products. Dave holds an MBA from The Tuck School at Dartmouth College and a BS in Mechanical Engineering from Worcester Polytechnic Institute.

Rob Friel served as the chairman and chief executive officer of PerkinElmer, a global leader in life sciences with a mission of innovating for a healthier world, from February, 2008 until his retirement in December 2019. From August 2007 to January, 2019, Mr. Friel also served as PerkinElmer's president. Since joining PerkinElmer in February 1999 as chief financial officer, Mr. Friel also held roles as chief operating officer and president of PerkinElmer's life and analytical sciences unit. Prior to joining PerkinElmer, he held senior management positions with AlliedSignal, now Honeywell International. Mr. Friel currently serves as a member of the board of directors of West Pharmaceutical Services, NuVasive, New York Life, and chairman of the board of directors of Xylem. He also is an advisor to EQT Private Equity. Mr. Friel received a bachelor's degree from Lafayette College and a master's degree from Fairleigh Dickinson University.